Replimune
REPL | NASDAQ
$21.41
-$0.48 (-2.19%)
At close: Nov 16, 2026, 4:00 PM ET
$21.33
-$0.08 (-0.37%)
After-hours:
Nov 16, 2026, 7:48 PM ET
Replimune Company Profile
Company profile explainedCompany Profile
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Sushil Patel | Chief Executive Officer & Director |
| Emily Luisa Hill | Chief Financial Officer |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer |
| Camilo Garcia | Chief Human Resource Officer |
| Carolyn Trott | Senior Vice President of Quality Assurance |
| Kari Jeschke | Senior Vice President of Regulatory Affairs |
| Konstantinos Xynos | Chief Medical Officer |
| Michelle DiNapoli | Chief Commercial Officer |
| Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management |
| Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
| Philip Astley-Sparke | Executive Chairman |
| Shawn Glidden | Senior Vice President & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 8-K | Current Report |
| Aug 24, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 14, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 4 | Filing |
Replimune
| Country | United States |
| IPO Date | Jul 20, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 465 |
| CEO | Sushil Patel |
Contact Details
500 Unicorn Park Drive Woburn,
Massachusetts 01801 United States
Stock Details
| Ticker Symbol | REPL |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001737953 |
| CUSIP Number | 76029N106 |
| ISIN Number | US76029N1063 |
| SIC Code | 2836 |
Recent News
- 4 days ago / zacks.comREPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
- 15 days ago / zacks.comWall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
- 19 days ago / fool.comReplimune: 3 Key Takeaways for Long-Term Investors
- 19 days ago / seekingalpha.comReplimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
- 20 days ago / globenewswire.comReplimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
- 26 days ago / globenewswire.comReplimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
- 2 months ago / globenewswire.comReplimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
- 2 months ago / seekingalpha.comReplimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
- 3 months ago / globenewswire.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 3 months ago / globenewswire.comReplimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Add to Watchlist
Select watchlists to add or remove REPL